Scarica l'app Stockscreener
0.7314
1.57%
0.0113
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SCYX Giù?
Forum
Previsione
Frazionamento azionario
Scynexis Inc Borsa (SCYX) Ultime notizie
Millennium Management LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Jane Street Group LLC Buys New Holdings in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey - Defense World
Northern Trust Corp Has $186,000 Stake in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Scynexis resumes dosing in Phase III MARIO study after lengthy delay - MSN
SCYNEXIS resumes Phase 3 antifungal study after FDA lift By Investing.com - Investing.com South Africa
SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold - Insider Monkey
Scynexis resumes patient dosing in Phase 3 MARIO study - TipRanks
SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study - marketscreener.com
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX St - GuruFocus
GSK Involved in SCYNEXIS's Phase 3 Study Milestone Dispute | GSK Stock News - GuruFocus
SCYNEXIS resumes Phase 3 antifungal study after FDA lift - Investing.com Australia
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX Stock News - GuruFocus
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - The Manila Times
SCYNEXIS Restarts Critical Phase 3 Trial for Life-Threatening Infection, Faces $30M GSK Payment Battle - Stock Titan
SCYNEXIS Faces Challenges Amidst Antifungal Developments - TipRanks
Biosergen taps antifungal expert as board member - Biostock
FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approval - Endpoints News
SCYNEXIS (NASDAQ:SCYX) Now Covered by Analysts at StockNews.com - Defense World
SCYNEXIS Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Scynexis: Q1 Earnings Snapshot - CT Insider
SCYX Reports Strong Q1 Revenue, Progress in Clinical Trials | SCYX Stock News - GuruFocus
SCYX: Cash Reserves and Debt Repayment Update | SCYX Stock News - GuruFocus
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update | SCYX Stock News - GuruFocus
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
SCYNEXIS INC SEC 10-Q Report - TradingView
Sector Update: Health Care Stocks Fall Late Afternoon - marketscreener.com
News - Biostock
SCYNEXIS (SCYX) Projected to Post Earnings on Wednesday - Defense World
JPMorgan Chase & Co. Makes New Investment in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
SCYNEXIS, Inc. (NASDAQ:SCYX) Shares Sold by LPL Financial LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Begins Coverage on SCYNEXIS (NASDAQ:SCYX) - Defense World
GSK 'well positioned' for potential tariffs after beating forecasts - marketscreener.com
Aspergillosis Market Expected to Rise by 2034, Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, - Barchart.com
SCYNEXIS (NASDAQ:SCYX) Upgraded by StockNews.com to Hold Rating - Defense World
Blastomycosis Treatment Market Overall Study Report 2025-2032 | Janssen, Scynexis Inc, Novartis AG, Marck & Co. - openPR.com
Second-Generation Antifungal Aims to Address Invasive Fungal Disease - ContagionLive
Acute Vulvovaginal Candidiasis Treatment Market Poised - openPR.com
SCY-247 shows promise against resistant fungal infections By Investing.com - Investing.com South Africa
SCY-247 shows promise against resistant fungal infections - Investing.com
Breakthrough: SCYNEXIS's New Antifungal Drug Defeats 171 Resistant Fungal Strains in Latest Tests - Stock Titan
Aspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide - The Globe and Mail
SCYNEXIS (NASDAQ:SCYX) Lowered to Sell Rating by StockNews.com - Defense World
SCYNEXIS (SCYX) to Release Earnings on Thursday - Defense World
Research Analysts Issue Forecasts for SCYNEXIS FY2029 Earnings - Defense World
StockNews.com Downgrades SCYNEXIS (NASDAQ:SCYX) to Sell - Defense World
SCYNEXIS Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
SCYNEXIS Reports 2024 Financial Results and Updates - TipRanks
0.54%
1.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):